News Release 

Anti-inflammatory medicine can have a beneficial effect on depression

Research carried out by the national psychiatry project iPSYCH shows that arthritis medicine can have a beneficial effect on symptoms of depression

Aarhus University

The World Health Organization (WHO) calls depression one of the most serious mental disorders, and researchers around the world are trying to improve treatment of the disease.

Now in the largest meta-analysis ever carried out, researchers from iPSYCH have shown that medicine which inhibits inflammation such as e.g. arthritis medicine can also be effective in the treatment of people suffering from depression.

"Our study shows that a combination of anti-inflammatory medicine, which is what arthritis medicine is, and antidepressants can have an additional beneficial effect on patients with a depression. The effect was also present when anti-inflammatory medicine was compared with a placebo in patients with a physical disease and depressive symptoms," explains one of researchers behind the study, PhD student and medical doctor Ole Köhler-Forsberg from Aarhus University and Aarhus University Hospital, Psychiatry.

Six different medications showed an effect on depression

The analysis is based on 36 international studies with a total 9.422 patients who either suffered from depression or had depressive symptoms. The results have just been published in Acta Psychiatrica Scandinavica.

In addition to looking into arthritis medicine, the researchers also examined the effect of other forms of medication which have an anti-inflammatory effect, including glucocorticoids and the antibiotic minocycline, adrenocortical hormone and the statins that are used in the treatment of high cholesterol levels. All of them showed antidepressant effects.

"This definitely bolsters our chances of being able to provide personalised treatment for individual patients in the longer term. Of course we always have to weigh the effects against the potential side-effects of the anti-inflammatory drugs. We still need to clarify which patients will benefit from the medicine and the size of the doses they will require. The findings are interesting, but patients should consult their doctor before initiating additional treatment," says Ole Köhler-Forsberg.

He emphasises that the biggest challenge with depression is that we still do not know what triggers the disease in a particular individual.

"Some studies suggest that the choice of antidepressant can be decided by a blood sample that measures whether there is an inflammatory condition in the body. Other studies show that the same blood sample can be used as a guideline for whether a depressive patient can be treated with anti-inflammatory medicine that has a better effect when there is inflammation present at the same time as the depression. However, we need to verify these findings and examine which patients can benefit from this before it can be implemented in everyday clinical practice," Ole Köhler-Forsberg says.

Several treatment options on the horizon

"What's persuasive is that we've found that several of the anti-inflammatory drugs have what can be characterised as a medium to a large effect on depression and depressive symptoms, in particular because the results build on almost 10,000 people who have participated in the placebo-controlled studies with anti-inflammatory treatment," explains medical doctor and PhD Michael Eriksen Benros, who is research director at the Mental Health Centre Copenhagen.

He emphasises that "the results from the meta-analysis are particularly promising not only because of an effect of the anti-inflammatory medicine on its own but also due to the supplementary effect when the anti-inflammatory medicine is given simultaneously with the anti-depressants that are used today.

However, in many of the studies the depressive symptoms were a secondary goal, meaning that large-scale and well-executed studies with depression as the primary objective are still needed. These must also be sufficiently large to assess the most beneficial dose and length of treatment, and also to identify which group of patients with depression are most likely to benefit from a supplementary anti-inflammatory treatment.

The hope is that research into the link between the immune system and depression can in the longer term provide more treatment options - including with anti-inflammatory medicine and preferably guided by biomarkers - so we can improve the treatment of depression, which is an area of intensive research at the moment," says Michael Eriksen Benros.

###

Background for the results:

A meta-analysis is a method that makes it possible to combine the results from several studies to provide an overall result.

The study was carried out in a collaboration between researchers from Aarhus University and the Mental Health Centre Copenhagen, Copenhagen University Hospital.

iPSYCH is financed by the Lundbeck Foundation.

The results have been published in the article: Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: Meta-analysis of clinical trials in Acta Psychiatrica Scandinavica.

About iPSYCH

The national research project iPSYCH - which is financed by the Lundbeck Foundation - was established back in 2012 with the purpose of carrying out research into and finding the causes of five of the most serious mental disorders: autism, ADHD, schizophrenia, bipolar disorder (formerly manic depression), and depression.

iPSYCH's purpose back then and today is to lay the foundations for better treatment and prevention of mental disorders by mapping the factors that play a role for these diseases. By examining genetic and risk factors in more than 130,000 Danes both with and without mental disorders, iPSYCH sheds light on the complex interaction between heredity factors and the environment, which for some people result in them developing a mental disorder. The project examines the diseases from various angles, ranging from genes and cells to population studies, prenatal life to adult patient and from cause to symptom. iPSYCH is a national collaborative project between Aarhus University, the University of Copenhagen, the Central Denmark Region and the Capital Region of Denmark, as well as SSI, the Danish State Serum Institute.

Today iPSYCH is one of the world's largest studies of genetic and environmental causes of mental disorders and it now comprises more than 150 researchers within psychiatry, genetics and register-based research.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.